Navigation Links
Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
Date:8/6/2008

The Trial Demonstrated the Safety and Efficacy of the ORMD 0801- Oral

Insulin Capsule

JERUSALEM, Israel, August 6 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP)(http://www.oramed.com), a developer of oral delivery systems, announced today successful results from the clinical trial of its oral insulin capsule, ORMD 0801. The trial demonstrated that the product had a good safety profile and was well tolerated and effective in lowering blood glucose levels in patients with type 2 diabetes.

The study was conducted at Hadassah University Medical Center in Jerusalem and was a continuation of the successful Phase 1B trials that Oramed completed earlier this year.

This trial was the first to expose patients with type 2 diabetes to ORMD 0801 and its primary goals were to assess the safety, tolerability and pharmcodynamic effects in these patients.

ORMD 0801 was well tolerated by all patients and had a good safety profile; no serious adverse events were encountered throughout the study. In 6 of the 9 subjects analyzed, statistically significant reductions in glucose as well as C-peptide were observed.

"We are pleased with the results from the Phase 2A trial as they showed that ORMD 0801 was effective and there were no safety issues," said Oramed's Chief Scientist, Dr. Miriam Kidron. "We look forward to our next phase of testing and taking the next steps towards making an oral insulin capsule a reality for millions of diabetics around the world."

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's te
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
2. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
3. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
5. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
7. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
8. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
9. BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial
10. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
11. MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... FLINT, Mich. , Dec. 24, 2014  Diplomat ... largest independent specialty pharmacy, is proud to announce ... and quality at Diplomat, will take office as the ... 2015. The formal induction ceremony will take place Feb. ... which will be held at the Renaissance Center in ...
(Date:12/24/2014)... SCHOFIELD, Wis. , Dec. 23, 2014 ... and marketer of over-the-counter (OTC) medicinal and healthcare products, ... production of MigraPure® H, a hemp-based, advanced headache relief ... marijuana dispensaries in Colorado , ... . With the MigraPure H Advanced ...
(Date:12/24/2014)... SAN DIEGO , Dec. 23, 2014 ResMed ... a significant patent infringement action against Chinese medical device manufacturer ... Commission (ITC) ruled today that BMC,s masks listed below infringe ... advertising, or selling these masks in the United ... , iVolve N2 nasal mask , Willow nasal pillows ...
Breaking Medicine Technology:Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... , JOHANNESBURG, South Africa, Nov. 26 The 2009 ... Award in the Generic Pharmaceutical Market is presented to ... ) , For the Company of the Year Award, ... performance against key competitors: growth strategy and implementation, degree ...
... , WESTON, Fla., Nov. 25 American Scientific ... that they have opened a regional marketing and production management office ... location abroad, providing an essential gateway for the development and production ... adults to be distributed and sold globally. Currently the company ...
Cached Medicine Technology:Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 4American Scientific Resources Inc. Opens Shanghai Location 2
(Date:12/25/2014)... The microscopy market is estimated to ... $5,756.0 million by 2019. Optical microscopy is the ... microscopes product segment is expected to show the ... focus on nanotechnology, technological advancements, and increasing federal ... , Get Full Copy of Report @ ...
(Date:12/25/2014)... December 26, 2014 The report ... to 2023” focuses on the current treatment landscape, ... the colorectal cancer market. Stivarga is a drug ... or rectal cancer. Boehringer Ingelheim is developing nintedanib ... treatment of refractory CRC in the US, Europe, ...
(Date:12/25/2014)... “Every three months the trends for evening dresses ... be one of the hottest styles in the next few ... company releases 26 A-line sweetheart evening dresses, and announces the ... “We are trying our best to help a lady to ... with affordable prices, we provide discounted delivery costs to our ...
(Date:12/25/2014)... CA (PRWEB) December 25, 2014 The short ... was created in honor of a true 9/11 hero, ... two film festivals including the 24 hours of Nuremberg International ... in Bangladesh. , Actress, screenwriter and director Luciana ... produce this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... Woodland Hills, California (PRWEB) December 25, 2014 ... in her home in Woodland Hills, California after an ... Harris passed away on Christmas Eve evening in her ... battle with aggressive metastatic breast cancer. ... International for over forty years, she pioneered and championed ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... Prescribed TherapiesSACRAMENTO, Calif., May 11 The California chapter ... network of over 250 physicians with the shared mission ... treatments and therapies, today cited a recent survey of ... number of physicians believe insurance companies are getting in ...
... May 11 Cell Therapeutics, Inc. ("CTI" or the "Company") ... of Directors has authorized a "Modified Dutch Auction" tender offer ... of its common stock, no par value ("Common Stock"), and ... principal amount for the following outstanding shares of the Company,s ...
... . , Montreal, May 11, 2009 When ... an equal hand. The latest study by Dr. Maya Saleh, ... and McGill University, shows that women have a more powerful ... by females could have a beneficial effect on the innate ...
... The National Organization for Rare Disorders (NORD) will honor ... cutting-edge television network, and several pioneering companies developing treatments ... the National Press Club in Washington, DC, on Thursday, ... which researchers and others are honored for significant achievements ...
... Aon Corporation (NYSE: AOC ) Chairman, Lester B. ... 15, 2009 at 10:00 a.m. Central Time. A webcast of ... Chicago will be available via the Internet. This listen-only webcast ... web site at www.aon.com . The webcast ...
... 50 percent by the 14th test, study finds, , , MONDAY, ... you undergo, the higher your risk of having at least ... may seem like common sense, it,s not something that patients ... in the May/June issue of the Annals of Family ...
Cached Medicine News:Health News:Alliance for Patient Access Wants Health Care Code of Conduct 2Health News:Cell Therapeutics, Inc. Intends to Offer to Exchange up to $89.2 Million of its Outstanding Convertible Notes in a 'Modified Dutch Auction' Tender Offer 2Health News:Cell Therapeutics, Inc. Intends to Offer to Exchange up to $89.2 Million of its Outstanding Convertible Notes in a 'Modified Dutch Auction' Tender Offer 3Health News:Equality of the sexes? Not always when it comes to biology 2Health News:NORD to Honor Rare Disease Pioneers 2Health News:NORD to Honor Rare Disease Pioneers 3Health News:Aon to Webcast Annual Shareholders' Meeting 2Health News:More Cancer Tests Mean More False-Positive Results 2Health News:More Cancer Tests Mean More False-Positive Results 3
... Lyphochek Elevated Immunosuppressant Control is a ... whole blood. This unique product is ideal ... very high Cyclosporine levels, such as C2 ... patients at two hours post-dose., ,Lyphochek Elevated ...
Liquichek Hematology-16T Control is a hematology reference control used in monitoring determinations of blood cell values on TOA SYSMEX cell counters....
NEW Liquichek Reticulocyte Control (A)is an assayed whole blood control for evaluating the precision of automated methods of reticulocyte counting....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Medicine Products: